BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21374592)

  • 1. Osteopontin stimulates autophagy via integrin/CD44 and p38 MAPK signaling pathways in vascular smooth muscle cells.
    Zheng YH; Tian C; Meng Y; Qin YW; Du YH; Du J; Li HH
    J Cell Physiol; 2012 Jan; 227(1):127-35. PubMed ID: 21374592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OPN inhibits autophagy through CD44, integrin and the MAPK pathway in osteoarthritic chondrocytes.
    Bai RJ; Liu D; Li YS; Tian J; Yu DJ; Li HZ; Zhang FJ
    Front Endocrinol (Lausanne); 2022; 13():919366. PubMed ID: 36034459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteopontin Promotes Cell Migration and Invasion, and Inhibits Apoptosis and Autophagy in Colorectal Cancer by activating the p38 MAPK Signaling Pathway.
    Huang RH; Quan YJ; Chen JH; Wang TF; Xu M; Ye M; Yuan H; Zhang CJ; Liu XJ; Min ZJ
    Cell Physiol Biochem; 2017; 41(5):1851-1864. PubMed ID: 28376477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up regulation of isoleucyl-tRNA synthetase promotes vascular smooth muscle cells dysfunction via p38 MAPK/PI3K signaling pathways.
    Li B; Wang Z; Chen R; Hong J; Wu Q; Hu J; Hu Z; Zhang M
    Life Sci; 2019 May; 224():51-57. PubMed ID: 30905780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferative Vascular Smooth Muscle Cells Stimulate Extracellular Matrix Production via Osteopontin/p38 MAPK Signaling Pathway.
    Pei H; Zhang H; Tian C; Sun X; Qian X; Meng Y; Guo X; Chang Q
    Cardiology; 2021; 146(5):646-655. PubMed ID: 34186540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteopontin may be a driver of abdominal aortic aneurysm formation.
    Wang SK; Green LA; Gutwein AR; Gupta AK; Babbey CM; Motaganahalli RL; Fajardo A; Murphy MP
    J Vasc Surg; 2018 Dec; 68(6S):22S-29S. PubMed ID: 29402664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive regulation of the Egr-1/osteopontin positive feedback loop in rat vascular smooth muscle cells by TGF-beta, ERK, JNK, and p38 MAPK signaling.
    Yu HW; Liu QF; Liu GN
    Biochem Biophys Res Commun; 2010 May; 396(2):451-6. PubMed ID: 20417179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone-induced osteopontin expression in vascular smooth muscle cells involves MR, ERK, and p38 MAPK.
    Fu GX; Xu CC; Zhong Y; Zhu DL; Gao PJ
    Endocrine; 2012 Dec; 42(3):676-83. PubMed ID: 22588951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MCP-1 stimulates MMP-9 expression via ERK 1/2 and p38 MAPK signaling pathways in human aortic smooth muscle cells.
    Yang CQ; Li W; Li SQ; Li J; Li YW; Kong SX; Liu RM; Wang SM; Lv WM
    Cell Physiol Biochem; 2014; 34(2):266-76. PubMed ID: 25033895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P38 MAPK Signaling Pathway Mediates Angiotensin II-Induced miR143/145 Gene Cluster Downregulation during Aortic Dissection Formation.
    Li B; Wang Z; Hu Z; Zhang M; Ren Z; Zhou Z; Huang J; Hu X
    Ann Vasc Surg; 2017 Apr; 40():262-273. PubMed ID: 28167124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High glucose induces the expression of osteopontin in blood vessels in vitro and in vivo.
    Li T; Ni L; Liu X; Wang Z; Liu C
    Biochem Biophys Res Commun; 2016 Nov; 480(2):201-207. PubMed ID: 27743892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteopontin knockdown inhibits αv,β3 integrin-induced cell migration and invasion and promotes apoptosis of breast cancer cells by inducing autophagy and inactivating the PI3K/Akt/mTOR pathway.
    Zhang H; Guo M; Chen JH; Wang Z; Du XF; Liu PX; Li WH
    Cell Physiol Biochem; 2014; 33(4):991-1002. PubMed ID: 24714122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1.
    Nerurkar SS; Olzinski AR; Frazier KS; Mirabile RC; O'Brien SP; Jing J; Rajagopalan D; Yue TL; Willette RN
    Biomarkers; 2007; 12(1):87-112. PubMed ID: 17438656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of integrin beta3-FAK signaling pathway activated by osteopontin inhibits neointimal formation after balloon injury.
    Han M; Wen JK; Zheng B; Liu Z; Chen Y
    Cardiovasc Pathol; 2007; 16(5):283-90. PubMed ID: 17868879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of integrin and CD44 receptors recognising osteopontin in the normal and LPS-lesioned rat substantia nigra.
    Ailane S; Long P; Jenner P; Rose S
    Eur J Neurosci; 2013 Aug; 38(3):2468-76. PubMed ID: 23692556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis.
    Zheng W; Li R; Pan H; He D; Xu R; Guo TB; Guo Y; Zhang JZ
    Arthritis Rheum; 2009 Jul; 60(7):1957-65. PubMed ID: 19565503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteopontin stimulates apoptosis in adult cardiac myocytes via the involvement of CD44 receptors, mitochondrial death pathway, and endoplasmic reticulum stress.
    Dalal S; Zha Q; Daniels CR; Steagall RJ; Joyner WL; Gadeau AP; Singh M; Singh K
    Am J Physiol Heart Circ Physiol; 2014 Apr; 306(8):H1182-91. PubMed ID: 24531809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells.
    Lee JL; Wang MJ; Sudhir PR; Chen GD; Chi CW; Chen JY
    Cancer Res; 2007 Mar; 67(5):2089-97. PubMed ID: 17332338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osmotic and hypoxic induction of osteopontin in retinal pigment epithelial cells: Involvement of purinergic receptor signaling.
    Hollborn M; Brück R; Kuhrt H; Wiedemann P; Bringmann A
    Mol Vis; 2020; 26():188-203. PubMed ID: 32214785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication.
    Shirasaki T; Honda M; Yamashita T; Nio K; Shimakami T; Shimizu R; Nakasyo S; Murai K; Shirasaki N; Okada H; Sakai Y; Sato T; Suzuki T; Yoshioka K; Kaneko S
    Sci Rep; 2018 Sep; 8(1):13143. PubMed ID: 30177680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.